TY  - JOUR
T1  - Assessment of Early Cardiac Dysfunction Related to Cancer Therapy in Patients Receiving Hematopoietic Stem Cell Transplantation: An Echocardiographic Analysis
A1  - L. Wang
A1  - Y. Zhang
A1  - F. Gao
JF  - Asian Journal of Current Research in Clinical Cancer
JO  - Asian J Curr Res Clin Cancer
SN  - 3062-4444
Y1  - 2021
VL  - 1
IS  - 1
DO  - 10.51847/RJgSF3R2oc
SP  - 38
EP  - 48
N2  - Hematopoietic stem cell transplantation (HSCT) is an effective treatment for various blood cancers, but it carries a risk of developing cardiac dysfunction related to cancer therapy. This study aimed to investigate the occurrence of subclinical cancer therapy-related cardiac dysfunction (CTRCD) one year after HSCT and to explore clinical factors that may contribute to its development. The study included 55 patients who underwent either autologous or allogeneic HSCT. Echocardiographic evaluations were performed prior to transplantation and repeated at a 12-month follow-up to detect cardiac changes.

At one year post-transplant, 15 patients (27.3%) showed evidence of asymptomatic CTRCD, including 9 with mild and 6 with moderate dysfunction. A history of anthracycline chemotherapy was more frequent among patients with CTRCD (60%) compared to those without (22.5%). Similarly, the use of the BEAM conditioning regimen was associated with higher CTRCD incidence (33.3% vs. 5%). Subclinical cardiac dysfunction affects over a quarter of patients one year after HSCT. Prior exposure to anthracyclines and receiving the BEAM conditioning regimen appear to increase the likelihood of developing CTRCD.
UR  - https://galaxypub.co/article/assessment-of-early-cardiac-dysfunction-related-to-cancer-therapy-in-patients-receiving-hematopoieti-brw1wmpbwjtf055
ER  -